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Abstract
The aim of this paper was to select the most interesting Brazilian biopharmaceuticals, with the best market opportunity 
for production. The biopharmaceuticals filgrastim, infliximab, somatropin, imiglucerase, betainterferon and factor VIII 
were selected because they are not produced in Brazil and thus could increase the technological capacity of domestic 
production. The use of a data mining tool facilitated the results achieved here, using the patents deposited in several banks 
worldwide as the source information. The prospects and trends of producing biopharmaceuticals in Brazil are of great 
interest to the country to establish a competitive industry and reduce the vulnerability of the National Health System, 
such as display windows of opportunity, showing the possibility of moving towards the production of biopharmaceuticals.
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Introduction
The biotech industry is currently considered to be the most 
important source of new drug development, in addition to 
its role as a strategic social and economic sector. The phar-
maceutical industry invests millions of dollars each year on 
research to obtain new products, such as biomolecules, be-
cause innovation is the foundation of progress in the health 
sector. The development of biopharmaceuticals has created 
treatment options for some of the more complex and fre-
quent diseases, such as multiple sclerosis, Alzheimer’s dis-
ease, brain tumors, chronic lymphocytic leukemia, and can-
cer, among many other diseases.
Although the economic aspects of the global pharmaceutical 
market are changing with the development of biomolecules 
because of the resulting biotechnology knowledge and em-
ployment opportunities, biopharmaceuticals are still a mi-
nor portion of the total pharmaceutical market. The mar-
ket is profitable, but rapid growth is necessary to rapidly 
and effectively produce new biological drugs, also known as 
biopharmaceuticals, that have the same clinical application 
with equal safety, quality and efficiency. Thus, any technical 
modification may be evaluated using criteria acceptable to 
regulatory agencies.
In Brazil, the Unified Health System (Sistema Único de Saúde 
- SUS) and the policy of the Ministry of Health (Ministé-
rio da Saúde - MS) according to decree GM/MS no 2.981 
of November 26, 2009 require access for the population 
to specialized medicine, including some biopharmaceuticals. 
The attending specialist may prescribe drugs to patients 
with rare or chronic diseases or diseases that require special 
treatment, such as Gaucher’s disease, rheumatoid arthritis 
and multiple sclerosis. These medications are divided into 
three groups based on their characteristics and forms, with 
responsibility of different organization acquisition, such as 
the Federal, States and Cities of Brazil. The criterion for the 
division of the groups involves the complexity of the disease 
to be treated, including the implications of care and financial 
maintenance at the various levels of disease management. 
According to decree GM/MS no 2.981/2009, the Group 1 
has a great economic impact in Brazil because this group 
is the responsibility of the federation  for treating diseases 
with greater complexity, and drugs to treat diseases have a 
significant financial impact.
Sectorial policies directed by the federation through the SUS 
require access for the Brazilian population to drugs with a 
major financial impact for the Ministry of Health. As shown 
in Figure 1, expenditures on specialized medicines has grown 
every year; in 2011, 31% of the total amount spent on medi-
cine (strategic, basic biopharmaceuticals, oncology, among 
others) was directed to this specialized class of medications.
The “Complexo Industrial da Saúde or CIS” (Industrial 
Health Complex) is a cornerstone of the Brazilian program 
of action “Mais Saúde” (More Health). This front is intended 
to boost the industry, including the domestic pharmaceu-
tical and healthcare equipment sectors, to reduce Brazil’s 
dependence on imported products. Among its goals is to 
reduce the trade deficit to US$4.4 billion to develop tech-
Figure 1: The evolution of expenditures on medicines by the Ministry of Health. Source: Analysis DECIIS / SCTIE / MS data SCTIE / MS, 
SVS / MS and DAF / SCTIE / MS (Moysés Jr, 2011).
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nology for the local production of 20 strategic products of 
SUS to 2013. In 2008, the productive chain of health repre-
sented between 7% and 8% of the Gross Domestic Prod-
uct (Produto Interno Bruto - PIB), with mobilized funds of 
approximately R$160 billion of economy in the country 
(MDIC, 2011). About 10% of the population is actively em-
ployed in the industry. The Brazilian pharmaceutical market 
annually generates R$28 billion, with a high annual growth 
rate, placing it among the 10 largest in the world. However, 
these numbers may be even higher in the future because of 
the Productive Development Policy conducted by the Min-
istry of Industry and Trade and Development (Ministério da 
Indústria e Comércio e Desenvolvimento - MDIC), of which 
the CIS is one of the arms (Portal da Saúde, 2011).
Decree GM/MS no1.284 of May 26, 2010 defines the list of 
strategic products under the SUS and indicates the key play-
ers involved in promoting the CIS strategy, i.e., public and 
private producers as well as regulators and funding agencies. 
The decree also indicates which products should be subject 
to specific initiatives aimed at increasing local production, 
innovation, technology transfer and regulatory mechanisms. 
In this ordinance was included the product with purchase 
cost more than R$10 million, which are purchased with 
financing of 100% of MS in decree GM/MS no 2.981 of 
November 26, 2009.
To understand the motivation of this study, we must return 
to the 1990s, when the market opened to foreign compa-
nies. This event weakened the Brazilian health industry and 
increased the trade deficit, which grew from US$700 million 
at the end of the 1980s to a cumulative US$7.13 billion in 
2008. Brazil has become extremely dependent on products 
with a higher density of knowledge and technology. As an 
example, in 2008 alone, Brazil imported US$1.4 billion in 
vaccines, serum and blood products and exported US$37 
million in products with low added value. Changing this situ-
ation requires initiatives to make better quality products in 
order to be more competitive, improvements in the indus-
trial structure and the formation of public-private partner-
ships (PPPs), which provide economic and social benefits in 
return, such as increased industrial parks in the pharmaceu-
tical market that can expand the range of drug treatment 
and increased specialization of human resources in this area 
of technology due to the creation of more jobs in the coun-
try (Portal da Saúde, 2011).
I. Volume of Biological Products Marketed
The health sector requires innovation to progress. The 
United States understands this need and invested US$51.3 
billion for research and development in the pharmaceutical 
industry in 2005, of which US$18.5 billion went to the de-
velopment of biopharmaceuticals. It is noteworthy that the 
biotechnology-based pharmaceutical industry is currently 
the most important source of new drugs (Roche, 2007).
Both novel molecules and the products known as biosimilar 
are marketed . According to Gary Walsh (2006), the peri-
od from 2003 to 2006 was very interesting for the phar-
maceutical industry because the first biosimilar product 
was approved under the trade name Sandoz Omnitrope® 
(Novartis group), based on the product Genotropin® from 
the pharmaceutical company Pfizer, which was formulated 
with recombinant human growth hormone (recombinant 
hGH), also known as somatropin. The approval of the drug in 
Australia in 2005 and later in Europe and the United States 
in 2006 represents a milestone in this area, though its ap-
proval was not without controversy. However, the produc-
tion of a biosimilar requires the loss of the product’s patent 
protection, and some analysts have suggested that approxi-
mately 75 to 2006 approved therapeutic proteins would 
eventually become targets for the production of a biosimilar.
In 2006, the world market had 165 biopharmaceutical 
products, which received approval in the regulatory agen-
cies worldwide. The total value for the market in 2004 was 
US$33 billion and was estimated to reach US$70 billion by 
the end of the decade (actual data not confirmed). In this 
context, the erythropoietin molecule, also known as eryth-
ropoietin, alfaepoetina, recombinant human erythropoietin 
and EPO, is the biopharmaceutical market leader, reaching 
US$ 10.7 billion in worldwide sales in 2005 (Walsh, 2006). 
This position was maintained in the United States in 2010 
with the commercial product Epogen ® from Amgen Cor-
poration, the pharma industry leader in biotechnology. Table 
1 presents some data on this vaccine, along with other bi-
opharmaceuticals that are among the 20 most prescribed 
drugs in this country (Iskowitz and Arnold, 2011).
To understand this industry, Pavlou and Reichert (2004) con-
ducted a survey of the global market for the period from 
2005 to 2010, through discussions with executives from 
pharmaceutical and biotechnology industries. This study 
revealed that the future growth market for recombinant 
DNA (rDNA) was the major contributor to the economic 
prosperity of the global industry. Thus, the leading pharma-
ceutical companies that market these products expected an 
increase of US$19.7 million in 2004 to US$29.7 million in 
2010, absorbing 57% of the total market size of biotechnol-
ogy.  The actual data so far have not been confirmed.
 
1The term biosimilar used in Brazil is derived from the translation of the 
biosimilar, which is the reduction of “similar biological medicinal product” 
used by the European Agency for the Evaluation of Medicinal Products, 
EMEA (European Medicines Agency). However, other terms are used for 
biosimilars in different countries. The United States uses the term “follow-
on protein products”, Japan uses the term “follow-on Biologicals”, Canada 
uses the term “subsequent entry biologics”, and India uses the term bio-
generics, because the generic industry is fairly representative. (Peres, 2009 
and Fermam, 2010).
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Lanthier et al (2008) related the distribution of protein prod-
ucts for sale and the molecular weight due to the similarity 
of the structural or therapeutic use. Among the products 
that exceed US$250 million in sales, Lanthier et al suggest-
ed the following seven classes of products: erythropoietin 
(EPO), colony stimulating factors granulocyte (G-CSFs), 
insulin, interferon-beta (IFN-beta), a human Growth Hor-
mone (hGH), interferon-alpha (IFN-alpha) and monoclonal 
antibodies (mAb). Over 80% of the therapeutic products 
marketed in 2006 were the products of these seven classes. 
Lanthier et al also estimated an increase in the consump-
tion of medicines produced by biotechnology to reach more 
than a quarter of all spending on prescription drugs by 2010. 
Some of these drugs have a higher cost than the daily dose 
of the drug molecules and can cost between 10 and 20 times 
the value of the medicine.
II. Scenario Production of Biosimilars
Given this scenario for increasing the production of biop-
harmaceuticals, some companies may join the biotech mar-
ket after the patents on innovative medicines expire if they 
have the resources and expertise to produce biosimilars. As 
occurred with generic medicines, the production of “cop-
ies’’ of biological medicinal products may occur. Specifically, 
these drugs, called biosimilars, are similar, but not identical 
to their reference products of comparison (Peres, 2009 and 
Fermam, 2010).
The development of the biosimilars market is surrounded by 
several discussions in regulatory agencies around the world 
(FDA, EMEA, and ANVISA, among others). For generic drugs 
obtained by chemical synthesis, the information from the 
clinical trials of the innovator product are acceptable for the 
generic product and therefore require fewer demands from 
regulators, thereby promoting the rapid entry of new prod-
ucts into the market. However, for biotechnologically pro-
duced drugs, the active pharmaceutical ingredients (APIs) 
are much more complex for the structure and production 
process. Therefore, the quality assurance, safety and efficacy 
of biosimilars are still controversial (Fermam, 2010).
The production of biosimilars is an opportunity for tech-
nological advancement for Brazil provided that the country 
have the capability for increase domestic production; thus, 
already started the debate in agencies public to the estab-
lishment and definition of regulatory guidelines to ensure 
the comparability therapeutic of biosimilar medicinal. Some 
national companies have already identified this trend, as 
shown in a 2008 survey from the database of the National 
Health Surveillance Agency (Anvisa), which was able to iden-
tify seven registered national biopharmaceutical companies: 
Fiocruz, Cristália, Blausiegel, Eurofarma, Silvestre Lab, Aché 
and Prodotti (Padilha, Kropf and Baetas, 2009 and Fermam, 
2010).
III. Biopharmaceuticals
The original definition of biopharmaceuticals that was first 
agreed upon in the 1980s describes biopharmaceuticals 
as belonging to a class of therapeutic products produced 
through biotechnology techniques, i.e., by rDNA technology 
or hybridoma technology, in the case of products based on 
murine monoclonal antibodies. Thus, a protein to be con-
sidered as a biopharmaceuticals, should be evaluated by the 
bioprocess that was used in its obtaining. Conversely, thera-
peutic proteins that are obtained by direct extraction from 
a source, such as the insulin extracted from pancreatic tis-
sue from slaughtered animals and the blood clotting factors 
extracted directly from blood, are not considered to be a 
product of biopharmaceuticals. Therefore, we can define a 
biopharmaceutical drug as a protein or nucleic acid-based 











10a Epogen® Erythropoietin Amgen 3.2 3.3
11 a Remicade® Infliximab J&J/ Merck 3.2 3.3
12 a Enbrel® Etanercept Pfizer 3.3 3.3
14 a Avastin® Bevacizumab Roche 3.0 3.1
16 a Neulasta® Pegfilgrastim Amgen 3.0 3.0
18 a Humira® Adalimumab Abbott 2.5 2.9
20 a Rituxan® Rituximab Roche 2.6 2.8
Table 1. * API = active pharmaceutical ingredients
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product used for therapeutic or diagnostic purposes in vivo 
that is produced by processes that do not involve the direct 
extraction from a biological source (Walsh, 2002).
Therapeutic proteins can be classified into seven distinct 
groups: cytokines, hematopoietic growth factors, other 
growth factors, hormones, enzymes, clotting factors and 
monoclonal antibodies. These proteins often have complex 
structures, such as proteins that require post-translational 
modifications to achieve their full biological activity, which 
is essential for their use as a biopharmaceutical. Because of 
this limitation, most approved biopharmaceuticals are pro-
duced by cultivating mammalian cells because microbial cells 
and insect cells have limitations in their ability to correctly 
perform the required post-translational modifications (Mel-
lado and Castilho, 2008).
The post-translational modifications generally occur during 
the synthesis of these molecules, with an N-glycosylation as 
the most recognized form, and require an extensive number 
of processing steps that are performed in the endoplasmic 
reticulum and the Golgi complex. This modification is car-
ried out by eukaryotic cells, which are the most commonly 
used host for producing biopharmaceuticals. As already stat-
ed, mammalian cells exhibit the best metabolic capabilities, 
in particular, strains of cells from baby hamster kidney cells 
(BHK) and Chinese hamster ovary cells (CHO), which have 
become the preferred host cells in the biopharmaceutical 
industry because the glycosylation patterns characteristic 
of these cells are similar to human standards and are con-
sidered safe because many of the main viruses that cause 
disease in humans cannot replicate in them (Butler, 2008).
However, there are also therapeutic non-glycosylated pro-
teins, which are typically expressed in Escherichia coli or 
Saccharomyces cerevisiae, such as commercial insulin (Hu-
mulin® from Eli Lilly), which is obtained from the E. coli, 
with the same protein expressed in S. cerevisiae marketed as 
NovoLog® by Novo Nordisk (Gerngross, 2004).
IV. Technologies Employed for the Production of Bi-
opharmaceuticals
Unlike small molecules, which are normally synthesized in 
the chemical environment, most biopharmaceuticals are 
sufficiently complex to requiring their production in living 
systems, particularly by recombinant DNA technology. As 
such, the choice of host for recombinant expression has 
been continuously reevaluated, and much effort is directed 
to developing new expression systems for proteins with 
improved characteristics. The five major goals in evaluat-
ing hosts for the expression of proteins are as follows: the 
cost of production and purification; the ability to control 
the final product, including its post-translational processing; 
the amount of time needed to produce the purified protein 
from the gene; the agencies’ regulatory approval of a drug 
product produced in a newly developed expression system; 
and the royalties associated with the global production of a 
recombinant product in a particular host (Gerngross, 2004).
These hosts may be divided into four groups of cells: mi-
crobial, mammalian, insect and plant. Biopharmaceuticals are 
mainly produced by cultivating mammalian cells or animal 
cells for industrial use, such as CHO and BHK. However, 
plants have many advantages compared with traditional sys-
tems for producing biopharmaceuticals, including the low 
production cost, fast scheduling, the absence of human path-
ogens and the ability to produce complex proteins safely. 
Studies show that crop plants have been widely studied, with 
economic and security advantages compared with more 
conventional systems; furthermore, using plants for synthe-
sizing protein on a large scale is gaining support. The host 
plants most frequently used are tobacco, cereals, vegetables, 
fruits and vegetables (Ma, Christou and Drake, 2003).
Controlling the conditions of cell culture is important in 
producing proteins, and culture conditions, such as nutrient 
content, pH, temperature and concentrations of oxygen or 
ammonia, can significantly affect the structures of glycans 
found in recombinant proteins requiring post-translational 
modification (N-glycosylation). Thus, this system sensitivity 
is important to consider in producing biopharmaceuticals 
because it may result in a great heterogeneity of glycoforms 
resulting from an incomplete glycosylation process and a 
significant batch-to-batch variation during the production 
process. To maintain the product quality, it is important to 
understand the factors that cause variations in the post-
translational steps.
There are also a number of other possible post-translational 
protein modifications that can be characterized, such as the 
addition or removal of small organic waste products. An ex-
ample is the process of pegylation, e.g., adding polyethylene 
glycol (PEG) groups, which involves an additional chemical 
synthesis step on a therapeutic protein to improve its phar-
macological properties. This step can affect the structural 
integrity of the protein and should be monitored during the 
bioprocess for producing the biopharmaceutical.
The aim of this paper was to select the most interesting Bra-
zilian biopharmaceuticals, with the best market opportunity 
for production among those products on the lists of drugs 
and specialized strategic products in the ordinances of the 
Ministry of Health. Provide reliable information that could, 
say, point towards windows of opportunity (e.g. regarding 
the expiration of the patents rights) may be  contribution to 
the technologic knowledge where they found some biosimi-
lar drugs target that will be useful for the Brazilian health/
drug industry using the patents database focusing in goals 
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that could be manufacturer in a near future to enhance the 
competitive industry and develop technologies that improve 
changes in the needs of Brazilians.
Method
I. Selection of Biological Products
Selecting the biological products of Brazilian interest oc-
curred after defining the three major criteria. The first cri-
terion for this study is based on the product list consisting 
of 83 strategic products and selecting the drugs obtained by 
biological routes (Decree GM/MS no1.284 of May 26, 2010). 
The second criterion was based on the list of 20 drugs with 
the highest values approved by the MS in 2007 (Barbano, 
2008). Finally, to complement the choice of organic prod-
ucts of interest to this study, the third criterion was based 
on drugs form the centralized procurement of the Ministry 
of Health of Brazil but that are not distributed by Brazilian 
producers (GM/MS no 2.981 of 26 November, 2009).
II. Main technical and market information
Information on biopharmaceuticals was obtained from con-
sistent sources of information, derived from scientific (scien-
tific articles, MSc dissertations and PhD theses) and produc-
tion technology (patents deposits at the Instituto Nacional 
da Propriedade Industrial/ INPI and United States Patent and 
Trademark Office / USPTO). We evaluated information on 
the website of the Ministry of Health of Brazil, the websites 
of National and International Research Centers, the website 
of the World Health Organization (WHO), the websites of 
producers of biopharmaceuticals, documents of National 
and International Regulatory Agency and the current legisla-
tion in Brazil.
III. Evaluation of Patents
After defining the targets of interest, the patents for select-
ed organic products were analyzed to verify the possibility 
of producing them in Brazil and to evaluate the possibility of 
a future owner of the technology.
To evaluate the deposition priority in Brazil, the online pat-
ent database was searched, which contains the INPI pub-
lished papers since 1992, plus some patents in previous 
years. As a strategic search for data collection, we used the 
“advanced search” function with the name of the vaccine 
and its synonyms in the “title” and “abstract”. The synonyms 
were obtained through a program developed by Scifinder 
the Chemical Abstract Service (CAS) for use by researchers 
in life sciences and materials sciences.
To complement the assessment of technological production, 
the study was based on the search for the patent database 
Derwent Innovations Index / DII (Thomson Scientific / ISI 
Web Services) to select the documents deposited in the 
USPTO, using the “topic” with the name of the selected bio-
logical product and its synonyms for the documents made 
available until 9/29/2011. This survey was conducted in the 
database of granted patents (Patent Full-Text and Image Da-
tabase / PatFt) with documents since 1976 and requested 
patents (Patent Application Full-Text and Image Database / 
AppFt) with requests from 2001.
The USPTO was searched using the following steps: (1) 
search and extract patents in the database, (2) structure a 
database of selected patents, (3) import the data into a text 
mining  program, and (4) analyze the information by generat-
ing networks. Steps 3 and 4 were performed using Vantage 
Point version 7.1 because of its tools for text mining and 
correlating significant sets of structured textual data, such as 
databases, that can extract duplicate information to define 
variables and construct tables and graphs.
Results and Discussion
The biological products selected for this study are listed in 
Table 2. Products that are not produced in Brazil were cho-
sen because the purpose of this work is to produce biophar-
maceuticals that contribute to the technological advance-
ment and empowerment of national production with high 
added value products.
The list of drugs from the centralized procurement specialist 
already lists the betainterferon drugs imiglucerase and inflix-
imab. However, these drugs are also present on the strategic 
biopharmaceutical drug list described as being imiglucerase 
betainterferon glucocerebrosidase and the group of inter-
ferons. Additionally, somatotropin, filgrastim and factor VIII, 
which is a procoagulant factors, are also considered strategic 
products for the MS. The MS list of 20 approved drugs with 
higher values in 2007 include the proteins betainterferon, in-
fliximab, somatropin (or somatotropin) and imiglucerase. All 
of the organic products listed in Table 2 are not produced in 
the country, so they can be considered a market opportu-
nity for production in Brazil.
Another very important consideration is the expenditures 
of the Ministry to acquire these drugs, as well as the quan-
tity of purchased product to meet the Brazilian population’s 
demand. Table 3 shows the quantities and amounts approved 
2A process for extracting knowledge from large data banks using artificial 
intelligence techniques to find agreements/disagreements among entries, or 
groups of them, looking for patterns, anomalies, rules, etc. rendering data as 
useful information for decision making or evaluation of results.
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for each vial of biological product in 2009. From these data, 
it is possible to understand why biopharmaceuticals imiglu-
cerase (or glucocerebrosidase) and infliximab are both pre-
sent on the list of strategic medicines. Although the amount 
of somatropin acquired exceeds that of all other biopharma-
ceuticals presented, the cost to purchase and infliximab imi-
glucerase is far superior to this hormone. An increased need 
for these biological products could have a severe impact on 
the budget of the MS, which could compromise investments 
in health in other areas.
Identifying the producers of biopharmaceuticals, and there-
fore the technical information for the production thereof, is 
very important for directing future investments in industrial 
technologies. Thus, Table 4 presents some elements for a re-
search line of biotechnological processes. We can then see 
that the drugs listed in Table 3 with the highest costs are 
from one global supplier. Therefore, a new producer enter-
ing the market may lead to a decrease in the value of the unit 
price of each vial and therefore produce a great benefit for 
patients using these drugs. This statement is confirmed by 
evaluating factor VIII and the biopharmaceutical somatropin 
because these two biological products have a low unit value 
and are brought to market by at least four world producers.
The biopharmaceutical betainterferon is shown in Tables 3 
and 4 in two forms, 1a and 1b, and this term depends on the 
expression system used in its production. The difference in 
the molecular weight of the forms of the biopharmaceutical 
obtained at the end of the process may be approximately 
22,500 Daltons or 18,500 Daltons, for betainterferon 1a and 
betainterferon 1b, respectively. This difference in the struc-
ture of the molecule is very important for defining the biop-
harmaceutical purification process.
It is important to mention that the value shown in Table 
3 for the organic product filgrastim, which was purchased 
by the MS in 2009, is related to the drug in its simplest 
form of presentation under the trade name Neupogen®, 
i.e., the first-generation filgrastim commercial product. The 
drug Neulasta® is the second-generation injectable, cost-
ing about R$2,000, and is produced with a post-translational 
modification known as pegylation. This technique decreases 
the interval of drug dosing for the patient, requiring only a 
daily injection of a 6 mg under the skin after about 24 hours 
of the cycle of chemotherapy, which allows the drug to be 
released slowly in the body. However, the drug Neupogen® 
should be administered with greater frequency as deter-
mined by medical staff.
Biological products can be produced after the first patent 
expires, so the expected number of biosimilars is expected 
to increase after the release period of the first generation of 
biologically sourced drugs, which started in the mid-1980s, 
expires. Figure 2 shows a graph with the temporal end of the 
patent. The patents for the products Cerezyme® (imigluc-
Biopharmaceutical Therapeutic Class Indication
Betainterferon Cytokine Multiple sclerosis
Factor VIII Blood clotting factor Control and prevention of bleeding for patients with Hemophilia A
Filgrastim Growth factor Neutropenia (low neutrophil count)
Imiglucerase Enzyme Gaucher’s disease
Infliximab Monoclonal antibody Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease
Somatropin Hormone Deficiency of growth hormone (hGH) and Turner syndrome
Table 2: The biological products selected for study
Biopharmaceutical Amount Approved in Vial




Betainterferon 1a 428,879 149,924,809.89 349.57
Betainterferon 1b 279,285 40,182,512.00 143.88
Factor VIII 115,032 620,022.48 5.39
Filgrastim 106,058 3,287,798.00 31.00
Imiglucerase 124,518 180,375,000.00 1,448.59
Infliximab 40,331 59,248,043.76 1,460.04
Somatropin 1,956,710 42,943,698.00 21.95
Table 3: Expenditures of the MS in 2009 in purchasing the biological products selected for the study.
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Table 4: Identifying the technological interest in selected biopharmaceuticals.
1CHO = Chinese hamster ovary cells / 2BHK = baby hamster kidney cells
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Brazil’s goal should be to not be dependent on a single drug 
so that the population does not suffer from technological 
backwardness, which was established in the country after 
the market opened to foreign companies. An example of a 
biological product that has caused great inconvenience to 
the country and the world is the drug Cerezyme® (imiglu-
cerase), whose production was interrupted in 2010. A viral 
contamination of the equipment used to produce the me-
dicinal plant in Allston in the United States was identified, 
and the U.S. Agency for the Control of Drug Administration 
(FDA) temporarily suspended its production in June 2009, 
which compromised the supply of Cerezyme® , and patients 
who required the treatment had their medication dosage 
reduced in Brazil to reduce the demand for the period 
(Cerezyme, 2010).
Alternatively, because of the possible contamination of ex-
pression systems traditionally used by the pharmaceutical 
industry, such as mammalian CHO cells, some research 
centers are exploring the use of plants or plant cells to pro-
duce pharmaceuticals. The enzyme glucocerebrosidase is be-
ing produced by an Israeli company Protalix Biotherapeutics 
from carrot cells, which is in a phase III clinical trial phase 
(Kaiser, 2008). Additionally, plant cells offer several advan-
tages in producing a vaccine, such as a low production cost, 
fast scheduling, and the absence of pathogens, making them 
capable of producing complex proteins safely because they 
retain the initial stages of post-translational modification (N-
glycosylation). However, its modification of the oligosaccha-
ride and the further processing of glycans in the Golgi ap-
paratus differ from those in mammalian cells (Butler, 2008).
To complement the INPI patents with priority in Brazil 
erase) and Remicade® (infliximab) will expire in 2013 and 
2014, respectively. With these data, it is possible to imagine 
that many biosimilars will enter the market soon to com-
pete with these products of high added value.
However, a biosimilar product is faced with not only the 
problem of obtaining a protein that replicates the structure 
and conformation of the original product but also the dif-
ficulty in achieving the recording the product not innova-
tive. Long, costly clinical studies should be performed to 
compare the original and the biopharmaceutical biosimilar, 
which makes the process of biosimilars very difficult from 
a practical point of view. A major challenge in obtaining the 
approval of regulatory agencies worldwide is the analytical 
characterization of the translational modifications that oc-
cur in proteins, particularly the processes of glycosylation 
(addition of carbohydrate molecules) and phosphorylation 
(phosphate esterification reactions). However, these hin-
drances do not prevent the production of biosimilar prod-
ucts; otherwise, there would not be as many different com-
mercial products for somatropin and factor VIII produced 
from different expression systems (Table 4). Nevertheless, a 
biosimilar may not always be much less costly than the origi-
nal biopharmaceutical, as occurred with the introduction of 
generic medicines in the Brazilian market.
However, biosimilars are not the only means of addressing 
the demands of the population in need of expensive biologi-
cal products. A country must be able to maintain effective 
technological development to meet the needs of the nation 
and thus to achieve market innovations in order to grow 
and leverage the industry’s competitiveness in the country 
and the world, taking bolder steps toward economic and 
social progress.
Figure 2: The timeline for the expiration of patents for the commercial products of interest.
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but also patent applications that may contribute to future 
trends in producing biopharmaceuticals.
The database Derwent Innovations Index was used to 
achieve integration and program support for the Vantage 
Point text mining because of the large amount of data avail-
able for this study. However, the patents could also have 
been surveyed manually using the bank’s own data, which 
showed that inventors observe the country as a future own-
er of technology and potential consumer market. However, 
the Instituto Nacional de Propriedade Intelectual does not 
have a database that represents the full technological de-
posits, as can be seen in the number of patents filed during 
the period since 1987 (Table 5). To understand how the pro-
duction is linked to global technology, this study focused on 
patents in the USPTO, looking at not only granted patents 
Biopharmaceutical INPI USPTO (*)
Betainterferon 27 362





Table 5: The number of patents deposited in the INPI and USPTO (*) Patent Full-Text and Application Full Text.
is available by the USPTO if the number of documents is in 
the dozen.
The USPTO database is used to provide a larger degree 
of technological foresight to study each of the six selected 
biological products and thus to trace the technological tra-
jectory that was used after diagnosing a concrete platform 
technology for the production these drugs.
A more detailed study is presented in Figure 3, showing 
the network between patents granted and applied for on 
glucocerebrosidase. We note that some patents have no 
connection with others, meaning that the state of the art 
of these patents was probably not important for generat-
ing knowledge at that time. However, the cluster that owns 
the patent-pending US 2005147567, in Figure 3(B), demon-
strates that the information contained in other documents 
that formed this network is relevant and that it may bring a 
new product to market.
The patents should be assessed on not only the formation of 
the network but also the strength of its connection, i.e., how 
important is one patent to another. This graphical evaluation 
depicts connections and indicates a stronger connection by 
the presence of a line. Figure 3(A) shows an example for the 
granted patent US 6,841,617 and US 2002173586 requested. 
A second example is presented for patents US 6,518,239 
and US 2009117193, in Figure 3(C).
Table 6 shows the relevant information about the selected 
documents and their importance. Therefore, the primary 
cluster shown in Figure 3 represents the trend of techno-
logical development in the formulation of drugs. This trend 
is also related to the organic products selected in this arti-
cle, not only to glucocerebrosidase, because patents are not 
made exclusively to apply to a single biopharmaceutical.
The graphical information should be evaluated by reading 
the patent and only those associated patents that had a role 
in the text mining. Table 6 provides some of the relevant 
information about the available patents cited in Figure 3.
Patent US 6,518,239 shows the importance of pulmonary 
administration as an alternative route, which may offer sev-
eral advantages over subcutaneous administration. These 
advantages include the convenience of patient self-admin-
istration, the reduction of potential side effects, the ease of 
administration by inhalation, the disposal of needles and so 
forth.
Patent US 6,841,617 created an implant system as a carrier 
for medicines. The composition of these implants is based 
on an aqueous solution containing a biodegradable poly-
mer that is easily synthesized and handled and that acts as a 
promising carrier to promote cell proliferation and biosyn-
thesis, supporting physiological loads. The in situ gelling is 
based on injection systems and eliminates the need for sur-
gical procedures, offering advantages and the ability to form 
any required implant patent. US 2002173586, requested in 
2002, was granted a patent US 6,841,617 in 2005; there-
fore, the connection between these two documents is quite 
strong (Figure 3A).
The applications US 2005147567 and US 2009117193 were 
licensed as patent US 6,518,239 in 2003. The pharmaceuti-
cal composition has a high dispersion and upper inhalable 
aerosols and is therefore preferred for administration to the 
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Figure 3: Graph obtained after data mining extracted from the USPTO for patents on glucocerebrosidase using the program Vantage 
Point. (A) Connection between US 6,841,617 and US 2002173586; (B) Cluster US 2005147567; (C) Connection between US 6,518,239 
and US 2009117193.
lungs. The dry powder contains an active agent and a di-or 
tripeptide containing at least two leucyl residues. The com-
position is physically and chemically stable for storage.
Conclusions
The prospects and trends of producing biopharmaceuticals 
in Brazil are of great interest to the country to establish 
a competitive industry and reduce the vulnerability of the 
National Health System. The importance of obtaining these 
drugs domestically at lower cost could provide an important 
foundation for achieving economic and social benefits, such 
as an increased market share in industrial biotechnology, 
which expands the range of drug treatment and the spe-
cialization of human resources in this technology area. Most 
important, however, the production of biopharmaceuticals in 
Brazil would increase the public’s access to these specialized 
drugs for treating rare or chronic diseases as well as those 
that require special treatment.
But, despite the complexity of the subject matter, produc-
ing biological products has become a widely debated topic 
in both academic and industrial contexts. The challenges in-
volved in producing biological products drive research to 
answer the questions that arise throughout this work.
The Industrial Health Complex for Brazil needs to strength-
en its technology base to succeed in generating competi-
tive pharmaceutical companies.  However, the technology 
base can only be strengthened when technological devel-
opments in the country are able to meet market demand. 
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Patent Title Year Assignees Importance of Patent
US 6,518,239
Dry powder composi-
tions having improved 
dispersivity
2003 Inhale Therapeu-tic Systems, Inc. 
Administration of the medication 





2005 Battelle Memorial Institute 
Composition of aqueous biodegrad-
able polymer “thermogelling” and 
methods for using polymers to pro-






Intl Prop Services, 
Battelle Memorial 
Institute
Composition of aqueous biodegrad-
able polymer “thermogelling” and 
methods for using polymers to pro-
vide biodegradable implant in situ
US 2005147567 Compositions com-prising an active agent 2005
Nektar Therapeu-
tics
Administration of the medication 
upon presentation of the aerosol
US 2009117193
Compositions Com-
prising an Active 
Agent
2009 Nektar Therapeu-tics
Administration of the medication 
upon presentation of the aerosol
Partnerships between academia and public and private sec-
tors should be established to increase the rate of innovation 
and patent protection in Brazil and to master the scientific 
and technological knowledge in strategic areas to reduce 
the vulnerability of the National Health System. Only by col-
laborating will the country be able to establish a competitive 
industry for producing medicines for human use.
However, biosimilars are not the only way to meet the 
needs of the population for expensive biological products. 
A country must be able to effectively develop technology to 
meet its needs and thus grow and leverage the competitive-
ness of its industry in the country and the world in order to 
facilitate economic and social progress.
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